Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Goldschmidt

Showing results (451-460 of 475) with videos related to

Pageof 48
Sort By:
Leukemia|July 4, 2018
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysisBrian A Walker, Konstantinos Mavrommatis, Christopher P Wardell, et al.
Nature Genetics|August 20, 2013
Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma riskDaniel Chubb, Niels Weinhold, Peter Broderick, et al.
Investigative Radiology|May 24, 2023
Prediction of Bone Marrow Biopsy Results From MRI in Multiple Myeloma Patients Using Deep Learning and RadiomicsMarkus Wennmann, Wenlong Ming, Fabian Bauer, et al.
Nature Communications|August 17, 2023
Resolving the spatial architecture of myeloma and its microenvironment at the single-cell levelLukas John, Alexandra M Poos, Alexander Brobeil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2024
Genomic Classification and Individualized Prognosis in Multiple MyelomaFrancesco Maura, Arjun Raj Rajanna, Bachisio Ziccheddu, et al.
The Lancet. Oncology|August 12, 2016
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaShaji Kumar, Bruno Paiva, Kenneth C Anderson, et al.
Blood|June 10, 2018
Identification of novel mutational drivers reveals oncogene dependencies in multiple myelomaBrian A Walker, Konstantinos Mavrommatis, Christopher P Wardell, et al.
Leukemia|February 16, 2020
Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive diseaseMike J Mason, Carolina Schinke, Christine L P Eng, et al.
Hemasphere|October 13, 2025
Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN-HARMONY Alliance platformAdrian Mosquera Orgueira, Marta Sonia Gonzalez Perez, Mattia D'Agostino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2026
Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 TrialJia Xiang Jin, Varun R Ginde, Stefanie Huhn, et al.
Pageof 48

Showing results (451-460 of 475) with videos related to

Sort By:
Pageof 48
Leukemia|July 4, 2018
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysisBrian A Walker, Konstantinos Mavrommatis, Christopher P Wardell, et al.
Nature Genetics|August 20, 2013
Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma riskDaniel Chubb, Niels Weinhold, Peter Broderick, et al.
Investigative Radiology|May 24, 2023
Prediction of Bone Marrow Biopsy Results From MRI in Multiple Myeloma Patients Using Deep Learning and RadiomicsMarkus Wennmann, Wenlong Ming, Fabian Bauer, et al.
Nature Communications|August 17, 2023
Resolving the spatial architecture of myeloma and its microenvironment at the single-cell levelLukas John, Alexandra M Poos, Alexander Brobeil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2024
Genomic Classification and Individualized Prognosis in Multiple MyelomaFrancesco Maura, Arjun Raj Rajanna, Bachisio Ziccheddu, et al.
The Lancet. Oncology|August 12, 2016
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaShaji Kumar, Bruno Paiva, Kenneth C Anderson, et al.
Blood|June 10, 2018
Identification of novel mutational drivers reveals oncogene dependencies in multiple myelomaBrian A Walker, Konstantinos Mavrommatis, Christopher P Wardell, et al.
Leukemia|February 16, 2020
Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive diseaseMike J Mason, Carolina Schinke, Christine L P Eng, et al.
Hemasphere|October 13, 2025
Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN-HARMONY Alliance platformAdrian Mosquera Orgueira, Marta Sonia Gonzalez Perez, Mattia D'Agostino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2026
Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 TrialJia Xiang Jin, Varun R Ginde, Stefanie Huhn, et al.
Pageof 48